THM Capital Advisory advises Plasana Medical on its €4 million fundraising

THM Capital Advisory supports Plasana Medical in raising €4 million to accelerate the development of Plasana One®, a cold plasma device for chronic wounds.

Plasana Medical, a medtech created by the Plasma Physics Laboratory at École Polytechnique and CNRS and created by the TechnoFounders startup studio, announces a 4 million euros equity round, supplemented by non-dilutive funding (grants and bank loans).

This operation brings together TF Participations (funds managed by TechnoFounders), as well as several family offices and business angels.

Plasana Medical is developing Plasana One®, an innovative medical device to treat chronic wounds, including diabetic foot ulcers, venous leg ulcers, and bedsores.

Thanks to its proprietary multi-jet cold plasma technology, Plasana One® aims to accelerate healing by 30 to 50% while reducing the risk of infection.

The device is also distinguished by a treatment speed announced as significantly higher (6 to 12 times faster), a painless approach, and an adapted use at home, where the majority of patients are cared for.

The funds raised will finance the PLASANA GENESIS clinical trial currently underway, with the aim of obtaining the CE mark in 2026, preparing for marketing in Europe and launching the regulatory process in the United States.

Yves Matton (École Polytechnique), co-founder of TechnoFounders ten years ago and at the initiative of several deeptech projects including Plasana Medical, was appointed CEO of the company in May.

THM Capital Advisory acted as financial advisor to Plasana Medical, with a team composed of Thomas Mitard, Aurélien Prost and Ali Koçak.